PHARMACEUTICAL CARE FOR PATIENTS ON HERCEPTIN® (TRANSTUZUMAB): CASE REPORT

Authors

  • Juliana dos Santos Silva Instituto Federal de Educação Ciência e Tecnologia do Rio de Janeiro - IFRJ Rua Professor Carlos Wenceslau, 343 Realengo Rio de Janeiro - RJ, CEP: 21.715-000
  • Felipe Cyrino Rodrigues Clínica São Carlos - Saúde Oncológica Rua Humaitá, 296 - Botafogo Rio de Janeiro - RJ CEP: 22261-004
  • Raquel Rennó Braga Instituto Federal de Educação Ciência e Tecnologia do Rio de Janeiro - IFRJ Rua Professor Carlos Wenceslau, 343 Realengo Rio de Janeiro - RJ, CEP: 21.715-000

DOI:

https://doi.org/10.14450/2318-9312.v32.e1.a2020.pp23-29

Keywords:

pharmaceutical care, antineoplasic agents, health education, medication adherence

Abstract

Pharmaceutical care can contribute to the patient’s well‑being throughout the therapy and for medication adherence. This practice is based on the theoretical framework of Pharmaceutical Care that proposes a patient‑centered approach focused on the prevention, identification and resolution of drug therapy problems to promote positive results in people’s health. The present study aims to report the pharmaceutical care to patients treated with Herceptin® (trastuzumab) at an oncology clinic in Rio de Janeiro, Brazil. Four patients were followed during four months in 2016. The main drug‑related problem identified was adverse drug reactions. Pharmaceutical interventions were performed with patients and prescribers. The most frequent interventions were education about the disease and the treatment. Educational interventions have helped to improve patients’ understanding of the disease and treatment, contributing to pharmacotherapy adherence. The present study highlights the importance of pharmaceutical care and supports to improve the quality of life of patients followed.

Author Biographies

Juliana dos Santos Silva, Instituto Federal de Educação Ciência e Tecnologia do Rio de Janeiro - IFRJ Rua Professor Carlos Wenceslau, 343 Realengo Rio de Janeiro - RJ, CEP: 21.715-000

Acadêmica de Farmácia do Instituto Federal de Educação Ciencia e Tecnologia do Rio de Janeiro - IFRJ

Felipe Cyrino Rodrigues, Clínica São Carlos - Saúde Oncológica Rua Humaitá, 296 - Botafogo Rio de Janeiro - RJ CEP: 22261-004

Farmacêutico Generalista. Especialista em Farmácia Oncológica pela Universidade São Camilo.

Raquel Rennó Braga, Instituto Federal de Educação Ciência e Tecnologia do Rio de Janeiro - IFRJ Rua Professor Carlos Wenceslau, 343 Realengo Rio de Janeiro - RJ, CEP: 21.715-000

Farmacêutica Industrial graduada pela Pontifícia Universidade Católica do Paraná (2001). Possui mestrado (2010) e Doutorado (2015) em Ciências Farmacêuticas pela UFRJ. Possui experiência na área de nanotecnologia, mais especificamente na pesquisa e desenvolvimento de novas formulações. Atualmente é docente no Instituto Federal de Ciência e Tecnologia do Rio de Janeiro (IFRJ) e se dedica à pesquisa na área de produtos naturais marinhos e à projetos de extensão na área do Cuidado Farmacêutico na Atenção Básica. Tem interesse em trabalhos na área de ensino farmacêutico e educação interprofissional.

Downloads

Published

2020-06-01

How to Cite

Silva, J. dos S., Rodrigues, F. C., & Braga, R. R. (2020). PHARMACEUTICAL CARE FOR PATIENTS ON HERCEPTIN® (TRANSTUZUMAB): CASE REPORT. Infarma - Pharmaceutical Sciences, 32(1), 23–29. https://doi.org/10.14450/2318-9312.v32.e1.a2020.pp23-29

Issue

Vol. 32 No. 1 (2020)

Section

Original article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).